0001169245-22-000081.txt : 20220610
0001169245-22-000081.hdr.sgml : 20220610
20220610162034
ACCESSION NUMBER: 0001169245-22-000081
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220519
FILED AS OF DATE: 20220610
DATE AS OF CHANGE: 20220610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Humphries William D.
CENTRAL INDEX KEY: 0001674278
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38697
FILM NUMBER: 221009167
MAIL ADDRESS:
STREET 1: C/O STRATA SKIN SCIENCES, INC.
STREET 2: 5 WALNUT GROVE DRIVE SUITE 140
CITY: HORSHAM
STATE: PA
ZIP: 19044
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001169245
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030375697
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: (610) 981-6500
MAIL ADDRESS:
STREET 1: 1 GREAT VALLEY PARKWAY
STREET 2: SUITE 30
CITY: MALVERN
STATE: PA
ZIP: 19355
FORMER COMPANY:
FORMER CONFORMED NAME: Phase Biosciences Inc
DATE OF NAME CHANGE: 20061013
FORMER COMPANY:
FORMER CONFORMED NAME: DT BIOSCIENCES INC
DATE OF NAME CHANGE: 20020315
4/A
1
wf-form4a_165489241494222.xml
FORM 4/A
X0306
4/A
2022-05-19
2022-05-20
0
0001169245
PhaseBio Pharmaceuticals Inc
PHAS
0001674278
Humphries William D.
C/O PHASEBIO PHARMACEUTICALS, INC.
1 GREAT VALLEY PARKWAY, SUITE 30
MALVERN
PA
19355
1
0
0
0
Non-employee Director Stock Option (right to buy)
0.8419
2022-05-19
4
A
0
11842
0
A
2032-05-18
Common Stock
11842.0
11842
D
Restricted Stock Units
2022-05-19
4
A
0
2538
0
A
Common Stock
2538.0
2538
D
This amendment is being filed to correct an error in the total Stock Options and RSUs acquired by the Reporting Person. All other information set forth in the May 20, 2022 Form 4 remains correct.
The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date.
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date.
/s/ John P. Sharp, Attorney-in-fact
2022-06-10